[1. Kandolf Sekulović L. Toksična epidermalna nekroliza. U: Šimić D, Hadžigrahić N, urednici. Hitna stanja u dermatologiji. Sarajevo: Bosnalijek; 2011. str. 45-59.]Search in Google Scholar
[2. Lissia M, Mulas P, Bulla A Rubino C. Toxic epidermal necrolysis (Lyell’s disease). Burns 2010;36:152-63.10.1016/j.burns.2009.06.21319766401]Search in Google Scholar
[3. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 2007;25:348-9.]Search in Google Scholar
[4. Tartarone A, Lerose R. Stevens-Johnson syndrome and toxic epidermal necrolysis: what do we know? Ther Drug Monit 2010;32:669-72.]Search in Google Scholar
[5. French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Allergol Int 2006;55:9-16.10.2332/allergolint.55.917075281]Search in Google Scholar
[6. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007;62:1439-44.10.1111/j.1398-9995.2007.01553.x17983378]Search in Google Scholar
[7. Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y,Bork K, et al. An algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010;88:60-8.10.1038/clpt.2009.25220375998]Search in Google Scholar
[8. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44.10.1038/sj.jid.570103317805350]Search in Google Scholar
[9. Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987;123:1171-3.10.1001/archderm.1987.01660330082014]Search in Google Scholar
[10. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102:4134-9.10.1073/pnas.040950010255481215743917]Search in Google Scholar
[11. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.10.1038/428486a15057820]Search in Google Scholar
[12. Aguiar D, Pazo R, Durán I, Terrasa J, Arrivi A, Manzano H, et al. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol 2004;66:345-50.10.1023/B:NEON.0000014538.31561.bc]Search in Google Scholar
[13. Nassif A, Bensussan A, Dorothe´e G, Mami-Chouaib F, Bachot N, Bagot M, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002;118:728-33.10.1046/j.1523-1747.2002.01622.x11918724]Search in Google Scholar
[14. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004;114:1209-15.10.1016/j.jaci.2004.07.047]Search in Google Scholar
[15. Roujeau J. Immune mechanisms in drug allergy. Allergol Int 2006;55:27-33.10.2332/allergolint.55.27]Search in Google Scholar
[16. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004;123:850-5.10.1111/j.0022-202X.2004.23439.x]Search in Google Scholar
[17. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3.10.1126/science.282.5388.490]Search in Google Scholar
[18. Ito K, Hara H, Okada T, Shimojima H, Suzuki H. Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fasligand expression. Clin Exp Dermatol 2004;29:679-80.10.1111/j.1365-2230.2004.01635.x]Search in Google Scholar
[19. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003;162:1515-20.10.1016/S0002-9440(10)64284-8]Search in Google Scholar
[20. Dylewski ML, Prelack K, Keaney T, Sheridan RL. Asymptomatic hyperamylasemia and hyperlipasemia in pediatric patients with toxic epidermal necrolysis. J Burn Care Res 2010; 31:292-6.10.1097/BCR.0b013e3181d0f44820182382]Search in Google Scholar
[21. Wong KC, Kennedy PJ, Lee S. Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol 1999;40:131-4.10.1046/j.1440-0960.1999.00342.x10439522]Search in Google Scholar
[22. French LE, Prins C. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. In: Bolognia JL, ed. Dermatology. 2nd ed. St. Louis: Elsevier; 2008. p. 287-300.]Search in Google Scholar
[23. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.10.1046/j.1523-1747.2000.00061.x10951229]Search in Google Scholar
[24. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use ofSCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004;140:890-2.10.1001/archderm.140.7.89015262712]Search in Google Scholar
[25. Imahara SD, Holmes JH, Heimbach DM, Engrav LE, Honari SH, Klein M, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res. 2006;27:270-5.10.1097/01.BCR.0000216532.71360.9B16679892]Search in Google Scholar
[26. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005;153:241-53.10.1111/j.1365-2133.2005.06721.x16086734]Search in Google Scholar
[27. Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23:87-9.10.1097/00004630-200203000-0000411882797]Search in Google Scholar
[28. Fromowitz JS, Ramos-Caro FA, Flowers FP. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol. 2007;46:1092-4.10.1111/j.1365-4632.2007.03277.x17910723]Search in Google Scholar
[29. Coss-Bu JA, Jefferson LS, Levy ML, Walding D, David Y, Klish WJ. Nutrition requirements in patients with toxic epidermal necrolysis. Nutr Clin Pract. 1997;12:81-4.10.1177/0115426597012002819155407]Search in Google Scholar
[30. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33-40.10.1016/j.jaad.2007.08.03917919775]Search in Google Scholar
[31. Herndon D. Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg. 1995;180:340-2.]Search in Google Scholar
[32. Hanken I, Schimmer M, Sander CA. Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis. J Dtsch Dermatol Ges. 2010;8:341-6.10.1111/j.1610-0387.2009.07289_supp.x]Search in Google Scholar
[33. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139:26-32.10.1001/archderm.139.1.2612533160]Search in Google Scholar
[34. Stella M, Clemente A, Bollero D, Risso D, Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach: a retrospective analysis. Burns. 2007;33:452-9.10.1016/j.burns.2006.08.01417475410]Search in Google Scholar
[35. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25:81-8.]Search in Google Scholar
[36. Chaidemenos GC, Chrysomallis F, Sombolos K, Mourellou O, Ioannides D, Papakonstantinou M. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol. 1997;36:218-21.10.1046/j.1365-4362.1997.00192.x9159011]Search in Google Scholar
[37. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg. 2005;58:504-10.10.1016/j.bjps.2004.12.007]Search in Google Scholar
[38. Mladenović T, Kostić K, Kozarski J, Panišić M, Begović V, Kandolf Sekulović L, i sar. Toksična epidermalna nekroliza - Syndrom Lyell. U: Zbornik rezimea XV Beogradski dermatološki dani; 2010 Novembar 12-13; Beograd (Srbija). Beograd: Udruženje dermatovenerologa Srbije; 2010. p. 53 (PS-14).]Search in Google Scholar
[39. Reese D, Henning JS, Rockers K, Ladd D, Gilson R. Cyclosporine for SJS/TEN: a case series and review of the literature. Cutis. 2011;87:24-9.]Search in Google Scholar
[40. Arévalo JM, Lorente JA, González-Herrada C, Jiménez- Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48:473-8.10.1097/00005373-200003000-00017]Search in Google Scholar
[41. Gubinelli E, Canzona F, Tonanzi T, Raskovic D, Didona B. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol. 2009;36:150-3.10.1111/j.1346-8138.2009.00616.x]Search in Google Scholar
[42. Al-Shouli S, Abouchala N, Bogusz MJ, Al Tufail M, Thestrup-Pedersen K. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol. 2005;85:534-5.]Search in Google Scholar
[43. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998; 352:1586-9. 10.1016/S0140-6736(98)02197-7]Search in Google Scholar